Factor IX Antibodies

Santa Cruz Biotechnology offers a broad range of Factor IX Antibodies for research in coagulation and hemostasis. Factor IX Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Factor IX is a crucial component of the intrinsic pathway of blood coagulation, playing a vital role in the formation of thrombin and fibrin, which are essential for blood clotting. Deficiencies or dysfunctions in Factor IX can lead to hemophilia B, a genetic disorder characterized by prolonged bleeding and increased risk of hemorrhage. Understanding the function and regulation of Factor IX is critical for developing therapeutic strategies for coagulation disorders. Research focusing on Factor IX has significant implications for advancing treatments in hematological conditions. Investigating Factor IX mechanisms provides valuable insights into blood clotting pathways and potential therapeutic targets. Factor IX research contributes to developing improved treatments for bleeding disorders and understanding normal hemostasis. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of blood coagulation mechanisms and develop innovative therapeutic approaches.